Targeted inhibition of ILK in cancer cells by various strategies can also lead to suppression of the AKT signaling pathway, inhibition of cell cycle progression, reduced vascular endothelial growth factor (VEGF) secretion in vitro, and reduced tumor growth in vivo [21]. The gene discussed is ILK; the disease is cancer.